Navigation Links
Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data At The IDF's 20th World Diabetes Congress
Date:10/21/2009

MONTREAL, Oct. 21 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes. Data from the Phase 2 dose optimization study, which were used to determine the dose in the DEFEND trial, were presented at the International Diabetes Federation's 20th World Diabetes Congress currently taking place in Montreal, Canada.

In an oral presentation entitled "Otelixizumab - Dose regimen optimization of a humanized aglycosylated anti-CD3 monoclonal antibody in adult subjects with type 1 diabetes mellitus," Dr. Louis Vaickus, Chief Medical Officer at Tolerx, presented preliminary data from the Phase 2 otelixizumab dose optimization clinical study, referred to as TTEDD.

In a previous investigator-sponsored Phase 2 study, a high dose (48-64 mg) of otelixizumab was shown to preserve natural insulin production for up to 48 months after a single course of treatment. Subsequently, Tolerx initiated TTEDD to investigate alternative dosing regimens that would minimize adverse events, while maintaining durable clinical activity. A cumulative dose of 3.1 mg of otelixizumab administered over 8 days was identified as the optimized dose suitable for further evaluation. In TTEDD, this dosing regimen resulted in preservation of beta cell function (as measured by C-peptide, a common marker for endogenous insulin production) for up to 12 months in patients with autoimmune new-onset type 1 diabetes with no observation of significant safety issues.

About the DEFEND Study

DEFEND (Durable Response Therapy Evaluation
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Tolerx Announces Amendment to Phase 3 DEFEND Protocol
2. Tolerx Expands Phase 3 DEFEND Trial of Otelixizumab in Europe
3. Laureate Announces Manufacturing Agreement with Tolerx
4. Tolerx Named as One of the Fierce 15 Biotech Companies of 2008
5. Sinobiopharma Presents Highlights from Unaudited First Quarter Financial Results for the 3 Month Period Ended August 31, 2009
6. AlphaHelix Presents AmpXpress(TM) at the BIOTECHNICA Show
7. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
8. InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting
9. NovaBay(R) Presents Data Confirming Its Aganocide(R) Compounds Are Effective In Killing Bacteria That Have Developed Multidrug-Resistance
10. Novexel Presents 16 Posters and one Slide Presentation at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Meeting in San Francisco
11. Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... Agricultural firm H.J. Baker & Bro., Inc. ... Tiger-Sul. Since the purchase of Tiger Industries and ... 2005, H.J. Baker has leveraged the innovation of the ... portfolio of product offerings and solutions expertise. The deal ... innovation of Tiger-Sul, transforming the company into a leading ...
(Date:5/20/2015)... , May 20, 2015  Cypher Genomics, Inc., ... collaboration with Celgene Corporation to apply Cypher,s Coral ... that associate with patient response to innovative medicines. ... to help accelerate patient access to the right ... clinical research and development and potentially inform new ...
(Date:5/20/2015)... Carolina , 20. Mai 2015 ... für klinische Logistik (Clinical Logistics Organization/CLO) ... Geschäftsjahr 2014, das am 31. Dezember ... Unternehmen hat die Marktentwicklung übertroffen und ... - http://photos.prnewswire.com/prnh/20110930/NY78064LOGO ...
(Date:5/20/2015)... , May 20, 2015  HOSTING, the leading ... that it is an official partner of ... (CHIME) Cooperative Members Services Program. This unique ... managed cloud services and best practices derived ... CIOs and service providers, enabling member healthcare ...
Breaking Biology Technology:Agricultural Firm H.J. Baker & Bro., Inc., Celebrates 10 Years Since Acquisition Of Tiger-Sul 2Agricultural Firm H.J. Baker & Bro., Inc., Celebrates 10 Years Since Acquisition Of Tiger-Sul 3Cypher Genomics Collaborates with Celgene Corporation to Identify Novel Genomic Biomarkers 2Marken schließt Ergebnisse für das Geschäftsjahr 2014 ab 2HOSTING Named Partner of the CHIME Cooperative Member Services Program 2HOSTING Named Partner of the CHIME Cooperative Member Services Program 3
... 5 BioMarin,Pharmaceutical Inc. (Nasdaq: BMRN ) today ... present a company,update at the Credit Suisse 2008 Annual ... at 10:30 a.m. MST., Interested parties may access ... investor section of the BioMarin website, http://www.BMRN.com .,A ...
... (Nasdaq: PPHM ) today announced that senior ... Annual Healthcare Conference on,Tuesday, November 11, 2008 at ... at,the New York Palace Hotel in New York ... please visit:, http://www.rodmanandrenshaw.com/conferences?id=19 , About Peregrine Pharmaceuticals, ...
... EDMONTON, Nov. 5 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: ... today,announced that Mr. Kevin Giese, President and CEO, will present ... York., WHEN: Monday November ... New York Palace Hotel, New York., About BioMS Medical ...
Cached Biology Technology:BioMarin to Present at the Credit Suisse Healthcare Conference 2BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference 2
(Date:5/19/2015)... 18, 2015 Fingerprint Cards (FPC) has ... FPC1145, FPC1155 and FPC1035 from one if its module partners. ... including Q3 2015 and the sensors will be used by ... values for 2015 hereby amount to 740 MSEK to date. ... 140 MSEK and a number of smaller orders not separately ...
(Date:5/19/2015)... DUBLIN , May 19, 2015 /PRNewswire/ ... ) has announced the addition of the  ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A ... provides an in-depth analysis of the current ... introduction of gene-based tests, their working principles ...
(Date:5/14/2015)... Research and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) ... Market in Smart Mobile Devices " report to ... was a watershed year for fingerprint sensors in smartphones ... Apple gave fingerprint sensors a raison d,etre in the ... are a must-have feature in flagship smartphones. ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Global Genetic Testing Market Outlook 2018 2Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2
... that advanced biofuels made from cellulosic biomass are the ... renewable, clean, green, domestic source of transportation energy. Nature, ... sugars in grains, the complex polysaccharides in the cellulose ... woody material called lignin. For advanced biofuels to be ...
... Why do people with a hereditary mutation of the ... sickle-cell anemia prevalent in Africa) not contract severe malaria? ... of the Department of Infectious Diseases at Heidelberg University ... of the altered hemoglobin provides protection from severe malaria. ...
... recovery at one minute after a six-minute walking distance (6MWD) ... clinical worsening in patients with idiopathic pulmonary arterial hypertension (IPAH), ... first study to show that heart rate recovery at one ... strong predictor of clinical worsening in IPAH patients," said Omar ...
Cached Biology News:A corny turn for biofuels from switchgrass 2A corny turn for biofuels from switchgrass 3Protection from severe malaria explained 2Protection from severe malaria explained 3Heart rate recovery predicts clinical worsening in pulmonary hypertension 2
... Thermo Electron's CryoMed Freezers for IVF ... (K021042) with precise control, ease of setup ... temperature and operation status are continuously displayed ... and the cycle data are printed by ...
... Vacuum pumps deliver critical performance for all ... control optimizes pump performance to suit all ... for convenient checking of proper oil levels ... pumps is designed to work with all ...
A powerful, easy-to-use solution, the SORVALL RC12BP Blood Processing System allows you to manufacture blood components quickly and cost-effectively while ensuring product quality, safety, and GMP co...
Economical and manually filled LN2 vacuum insulated storage container offers high capacity and low nitrogen consumption while offering convenient storage of samples....
Biology Products: